Categories
Latest Industry Intelligence
AI in drug discovery eBook out now This 28-page DDW eBook, sponsored by Benchling, contains [...]
From AI to 3D deep-learning research to biologics, Lu Rahman selects some interesting global start-ups [...]
30 June 2020 Image: Glen Carrie In lab tests, virus-like DNA structures coated with viral proteins provoke a strong immune response in human B cells, by Ann Trafton, MIT News Office By folding DNA into a virus-like structure, MIT researchers have designed HIV-like particles that provoke a strong immune response from human immune cells grown in a […]
Computational modeling yields a protein fragment that could bind to coronavirus spike proteins and destroy them by Anne Trafton, MIT News Office The research described in this article has been published on a preprint server but has not yet been peer-reviewed by scientific or medical experts. Using computational models of protein interactions, researchers at the MIT Media […]
The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 – Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered regularly-interspaced short palindromic repeats (CRISPR) were first detected in […]
Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 – Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic diseases and cancer has never been greater. […]
ADCs and solid tumours – The payload revolution that drives therapeutic opportunities in unmet need By Dr Jenny Thirlway Volume 21 Issue 2 – Spring 2020 The fight against cancer is ongoing. Despite progress in many indications, mortality rates for some of the most difficult to treat solid tumour types have not improved substantially since […]
Innovative glycan imaging methods drive cancer biomarker discovery By Dr Richard Drake, Dr Anand Mehta and Dr Peggy Angel Volume 21 Issue 2 – Spring 2020 Glycosylation accounts for the majority of post-translational modifications (PTMs) of proteins, and changes in glycosylation are known to play a key role in disease state. Novel mass spectrometry (MS) […]
Target discovery and drug development what comes after CRISPR? By Benedict CS Cross Volume 21 Issue 2 – Spring 2020 For an area of research as important and impactful as drug discovery, it is surprising how often efforts in this field are directed by short-term trends. We have seen an abundance of new tools and […]
Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 – Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering, has been the driving force in biomedical […]
Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace the expectations of ’omicsbased healthcare interventions, from the increased […]
Getting a handle on liquids: automation solutions for drug discovery By Helen Stewart-Miller and Thomas Hope The accurate and precise measurement of liquids and the transport of exact volumes between vessels, or from one instrument to another, are processes that constitute the very essence of research. However, while this simple requirement for the meticulous handling […]